InnerDyne/U.S. Surgical
This article was originally published in The Gray Sheet
Executive Summary
USSC is discontinuing development and plans to commercialize InnerDyne's EnAbl thermal endometrial ablation system for treatment of excessive uterine bleeding, InnerDyne reports Aug. 28. InnerDyne cites as a possible reason for the decision USSC's acquisition of a "competing technology" via its $425 mil. Valleylab purchase in February. The move follows FDA's March approval of USSC's product development protocol for the system ("The Gray Sheet" March 16, In Brief). The two firms agreed to a marketing deal for the product in early 1997